High Court of Delhi provides guidance on data submission in patent applications

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

High Court of Delhi provides guidance on data submission in patent applications

Sponsored by

rna-400px.jpg
Parmaceuticals production with data analysing graphic

Ranjan Narula and Suvarna Pandey of RNA Technology and IP Attorneys discuss a case that centred around the submission of data in support of an enhanced therapeutic efficacy claim for a compound

On November 22 2023, a decision by the High Court of Delhi clarified the recommended practice concerning the submission of data to support patent applications at the Indian Patent Office, with reference to Section 3(d) of the Patents Act, 1970 (the Patents Act).

The issue arose in the context of patent application No. 9739/DELNP/2011, filed by Ischemix LLC, titled 'Compositions and Methods for Treating Ischemia and Ischemia-Reperfusion Injury'. The application was refused by the Indian Patent Office under Section 3(d) of the Patents Act. Ischemix LLC filed an appeal before the High Court of Delhi under Section 117A of the Patents Act, challenging the order of the controller refusing the patent application.

The arguments presented to the High Court of Delhi

In its appeal to the High Court of Delhi against the refusal order, the applicant argued that the data on the therapeutic efficacy of the claimed compound that was submitted had not been referred and that there was no discussion in respect of the same in the impugned order. The therapeutic efficacy of the claimed isomer was demonstrated by:

  • Submitting data relating to in vitro and in vivo studies, and clinical trials; and

  • The filing of reports by two experts to support the plea for enhanced therapeutic efficacy.

The counsel on behalf of the Indian Patent Office submitted the following:

  • A statement that “the Appellant may have given some data in support of the claim for enhanced efficacy, but failed to show how the same constituted therapeutic efficacy”.

  • In an email note filed by the appellant, “a clear and definitive explanation has been given on how the Appellant wishes to substantiate its claim of enhanced therapeutic efficacy. The same was not presented during the course of patent prosecution. Thus, the Patent Office is willing to reconsider and re-examine the subject patent application.”

The court’s findings

The court, after hearing both parties, observed that the settled position with the Supreme Court ruling in Novartis on Section 3(d) is “that whenever any patent Applicant wishes to place on record and demonstrate therapeutic efficacy… the same has to be done precisely. The Applicant must ensure that comparative tables, and a clear explanation as to the way the new form of the known substance has significant enhancement in therapeutic efficacy is placed before the Patent Office during prosecution of the application. The same could be in the form of comparative tables, in-vitro and in-vivo data [and] also clinical trial data.”

The court also discussed a relevant extract from DS Biopharma v The Controller of Patents and Designs and Anr. with regard to the directions to be followed by patent applicants while attempting to overcome the objections under Section 3(d) of the Patents Act, 1970:

“i) The Appellant shall file its response on the basis of the identified known substances and the extracts of the impugned order as set out above. In response, the Appellant may also produce efficacy data and support its submissions as to how Section 3(d) is not applicable.

ii) The said response shall be filed by the Appellant within a period of 8 weeks – upon which, a fresh hearing shall be granted on the issue of whether the claims 1–4 are liable to be granted or not in view of the objections under Section 3(d) of the Act.”

Practice directions for the use of data in patent applications

The court thus issued the following practice directions:

  • For a patent application relating to derivative compounds, “the patent specification, itself, ought to contain some data and results of lab experiments which demonstrate enhancement of efficacy of the subject invention for which [a] patent is sought”; and

  • If additional data “becomes available, the said data ought to be submitted by the patent Applicant, and be placed before the Patent Office prior to the date of final oral hearing”.

Finally, the court noted that patent applicants often file experimental data at the stage of final written submissions. At this stage, the oral hearings before the Patent Office are concluded and the data may not be referred during oral hearings. This may lead to a situation, as in the present case, where the Patent Office is likely to have overlooked the data and failed to consider the same.

There is also the possibility of the data not being completely understandable in written submissions without oral explanation. Therefore, the experimental data for the therapeutic efficacy of a derivative compound should be submitted before the hearing, for the consideration of the controller, in the form of comparative tables, in vitro or in vivo data, or clinical trial data, with a clear explanation as to how the new form of the known substance has significant enhancement in therapeutic efficacy.

more from across site and SHARED ros bottom lb

More from across our site

Value-added services give in-house counsel the satisfaction that they are getting more value for money, while law firms get the opportunity to win more work
A team at Boies Schiller Flexner is advising shoe company Kizik and parent company HandsFree Labs in the dispute
Nokia’s latest enforcement actions against Geely and Transsion joining Via LA’s AAC pool were also among the top talking points
Benjamin Kelly, the firm’s fifth IP partner hire in a little over one year, has experience in patent and trade secret disputes involving complex technologies
Half-year Talent Tracker data shows Pierson Ferdinand was among the most prolific hirers in the US, while in Europe, there has been a notable UPC swing
Exclusive data reveals in-house counsel want external legal advisers to build better client relationships and add value beyond routine work
Brett Sandford acted for Perplexity AI, which fended off the threat of a preliminary injunction to launch an AI-powered web browser
Stephen Yang joins us for our ‘Five minutes with’ series to explain why his role requires him to wear many hats
The complaint follows a declaratory ruling issued by the England and Wales High Court last month that said Samsung is entitled to an interim licence
Tobias Hahn explains how the firm's multi-jurisdictional setup enabled it to secure an injunction on behalf of Fujifilm relating to defendant Kodak’s non-UPC activity
Gift this article